Atypical antipsychotics in persons with developmental disabilities

Aman, Michael G.; Madrid, Annette

doi:10.1002/(sici)1098-2779(1999)5:4<253::aid-mrdd2>3.3.co;2-i

Cited by 9 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Use of atypical antipsychotics has become more common during the study period (20% at Time 1; 30% at Time 4), consistent with recent reports in the literature that these medicines are being used to reduce irritability, behavior problems, and repetitive behaviors in individuals with ASD and developmental disabilities (Aman & Madrid, 1999; McDougle et al, 2000), to treat mood disorders (Keck, 2005), and consistent with advantages over typical antipsychotics in terms of neurological side effects and possibly in therapeutic effects. Two recent reviews of trials with atypical antipsychotics among individuals with ASD revealed a pattern of varied results (Myers, 2007; Posey, Stigler, Erickson & McDougle, 2008).…”

Section: Discussionsupporting

confidence: 80%

A Longitudinal Investigation of Psychotropic and Non-Psychotropic Medication Use Among Adolescents and Adults with Autism Spectrum Disorders

Esbensen

Greenberg

Seltzer

et al. 2009

J Autism Dev Disord

Self Cite

201

145

View full text Add to dashboard Cite

Medication use was examined in 286 adolescents and adults with ASD over a 4.5 year period. A total of 70% were taking a psychotropic or non-psychotropic medication at the beginning of the study. Both the number of psychotropic and non-psychotropic medications taken, and the proportion of individuals taking these medications, increased significantly over the study period, with 81% taking at least one medication 4.5 years later. Our findings suggested a high likelihood of staying medicated over time. Thus, adolescents and adults with ASD are a highly and increasingly medicated population. KeywordsASD; medication; psychotropic medication; non-psychotropic medication Individuals with autism spectrum disorders (ASD) have persistent impairments across the life course and therefore have an ongoing need for services and treatment, often including medications (Aman, Lam, Van Bourgondien, 2005;Martin, Scahill, Klin & Volkmar, 1999). Only one medication, risperidone, has been approved by the Food and Drug Administration specifically for use among individuals with ASD who have serious behavior problems (Scahill, Koenig, Carroll & Pachler, 2007) and there are few clinical studies addressing the effectiveness of medications in this population (Matson & Dempsey, 2008). There is a limited, but growing, body of research on psychotropic medications used by individuals with ASD. Traditionally, most trials in the population have been open label (Matson & Dempsey, 2008), although controlled trials are becoming more common (Myers, 2007). Whereas advances have been made in pharmacological management of children with ASD (RUPP, 2002(RUPP, , 2005, less is known about medication treatment for adolescents and adults with this diagnosis (Broadstock, Doughty & Eggleston, 2007). Similarly, although there are several studies of medication prevalence in children and adolescents with ASD (Aman, Lam & Collier-Crespin, 2003;Aman, Van Bourgondien, Wolford & Sarphare, 1995;Langworthy-Lam, Aman & Van Bourgondien, 2002;Witwer & Lecavalier, 2005), less is known about the prevalence of medication during adolescence and especially adulthood in this population, which is the focus of the present study.Correspondence concerning this article should be addressed to Anna J. Esbensen, Waisman Center, rm 561, University of WisconsinMadison, 1500 Highland Avenue, Madison, WI, NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author ManuscriptThe prevalence of prescription medications for children with ASD is high. Surveys indicate that one-half to two-thirds are prescribed at least one medication of any type, and about 45% are prescribed at least one psychotropic medication (Aman et al., 2005;Witwer & Lecavalier, 2005). The most commonly prescribed psychotropic medications are antidepressants, stimulants, and antipsychotics (Langworthy-Lam et al., 2002;Martin et al., 1999). However, non-psychotropic medications are also prescribed at high rates for individuals with ASD, although few studies have been conducted to benchmark the prevalence of medic...

show abstract

Section: Discussionsupporting

confidence: 80%

A Longitudinal Investigation of Psychotropic and Non-Psychotropic Medication Use Among Adolescents and Adults with Autism Spectrum Disorders

Esbensen

Greenberg

Seltzer

et al. 2009

J Autism Dev Disord

Self Cite

201

145

View full text Add to dashboard Cite

show abstract

“…The package insert for chlorpromazine indicates that it is also approved for the treatment of disruptive behavior in children, though not specifically for within IDD. serotonin and glutamate) (Aman & Madrid, 1999). The first generation antipsychotics (e.g.…”

Section: Atypical Antipsychoticsmentioning

confidence: 99%

Pharmacological Intervention for Disruptive Behaviors in Intellectual and Developmental Disabilities

Farmer

Aman²

2013

Challenging Behavior

Self Cite

View full text Add to dashboard Cite

“…Clozapine, olanzapine, and quetiapine all block both D 1 and D 2 dopamine receptor subtypes, together with several types of 5-HT receptor and a variety of other receptors including adrenergic receptors, whereas risperidone blocks D 2 , 5-HT, and adrenergic receptors (Aman & Madrid, 1999). In a systematic review of studies using atypical antipsychotics to treat persons with intellectual disabilities and/or autism published up to and including 1999, Aman andMadrid (1999) identified nine studies on children and adolescents or on mixed child/adult samples, seven on risperidone, and one each on olanzapine and clozapine.…”

Section: Atypical Antipsychoticsmentioning

confidence: 99%

“…In a systematic review of studies using atypical antipsychotics to treat persons with intellectual disabilities and/or autism published up to and including 1999, Aman andMadrid (1999) identified nine studies on children and adolescents or on mixed child/adult samples, seven on risperidone, and one each on olanzapine and clozapine. Several of these studies reported improvement in SIB in some participants.…”

Section: Atypical Antipsychoticsmentioning

confidence: 99%

Treating Childhood Psychopathology and Developmental Disabilities

2009

View full text Add to dashboard Cite

Atypical antipsychotics in persons with developmental disabilities

Cited by 9 publications

References 0 publications

A Longitudinal Investigation of Psychotropic and Non-Psychotropic Medication Use Among Adolescents and Adults with Autism Spectrum Disorders

A Longitudinal Investigation of Psychotropic and Non-Psychotropic Medication Use Among Adolescents and Adults with Autism Spectrum Disorders

Pharmacological Intervention for Disruptive Behaviors in Intellectual and Developmental Disabilities

Treating Childhood Psychopathology and Developmental Disabilities

Contact Info

Product

Resources

About